Nanotechnology Now

Our NanoNews Digest Sponsors





Heifer International

Wikipedia Affiliate Button


android tablet pc

Home > Press > OICR and MaRS Innovation announce funding for the development of Cellax™, a nanotechnology-based cancer drug

Abstract:
The Ontario Institute for Cancer Research (OICR) and MaRS Innovation (MI) today announced $1.5 million in funding from OICR over three years to further develop Cellax™, a nanoparticle drug that could offer an alternative to chemotherapy with fewer side effects.

OICR and MaRS Innovation announce funding for the development of Cellax™, a nanotechnology-based cancer drug

Toronto, Canada | Posted on November 14th, 2012

"Cellax is promising because it provides a more targeted strategy for treating tumours, killing tumour cells while minimizing the effect on healthy tissue," said Dr. Rima Al-awar, Director, OICR's Medicinal Chemistry Platform. "OICR is proud to invest in a technology that has such potential to one day improve quality of life for cancer patients."

Cellax, invented by Dr. Shyh-Dar Li and his research team in OICR's Medicinal Chemistry Platform group, is a drug-polymer conjugate based on Dr. Li's proprietary NanoCMC™ technology. These polymers self-assemble into defined nanoparticles and, when injected, selectively accumulate in tumours. Because of this property, the drug is released where it is most needed, increasing therapeutic benefits and reducing the side effects associated with conventional chemotherapy.

With the new funding, the Cellax team will conduct the pre-clinical manufacturing and toxicology studies necessary to bring Cellax to a clinical trial in cancer patients.

"Tumours are by nature more permeable to nano-sized molecules than normal tissue," says Li. "We are developing Cellax to exploit this weakness. We hope to use the NanoCMC platform to deliver drugs that will build up only in tumours. This would spare patients the side effects associated with less targeted treatments, which damage healthy cells as well as tumours."

Cellax, which is made from biocompatible components, is stable in storage and outperforms conventional chemotherapy in pre-clinical models of human tumours.

OICR is supporting the Cellax project through its Intellectual Property Development and Commercialization (IPDC) Fund, which was established to bridge the gap in the commercialization process between public funding agencies and private investors. All IPDC candidate projects are rigorously reviewed by external subject-specific experts in business and technology.

"MaRS Innovation provided the Cellax project with early-stage funding along with business development and management through our high-touch, embedded model," said Dr. Raphael Hofstein, president and CEO of MaRS Innovation. "MI continues to lead Cellax's commercialization strategy. We believe Cellax meets a clear clinical need within the multibillion-dollar Taxane market, and we anticipate that Cellax will emerge as a significant new player."

####

About Ontario Institute for Cancer Research
OICR is an innovative cancer research and development institute dedicated to prevention, early detection, diagnosis and treatment of cancer. The Institute is an independent, not-for-profit corporation, supported by the Government of Ontario. The annual budget for OICR, its research partners and collaborators exceeds $150 million. This supports more than 1,600 investigators, clinician scientists, research staff and trainees located at its headquarters and in research institutes and academia across the Province of Ontario. It has research hubs in Hamilton, Kingston, London, Ottawa, Thunder Bay and Toronto. OICR has key research efforts underway in small molecules, biologics, stem cells, imaging, genomics, informatics and bio-computing. For more information, please visit the website at www.oicr.on.ca

About MaRS Innovation

MaRS Innovation (MI) is the commercialization agent for the exceptional discovery pipeline from 16 leading Ontario academic institutions. As a single-entry point to total member research activity of $1 billion in annual research and development, MI provides an easy gateway for investors and licensees who wish to access technology assets in Ontario. Supported by the Government of Canada through the Networks of Centres of Excellence, by the Government of Ontario through the Ontario Centres of Excellence, and by its member institutions, MI is a transformational partnership that turns research strengths into real commercial opportunities. MI's portfolio includes the most promising assets and advances commercialization into global markets through industry partnerships, licensing and company creation.

For more information, please click here

Contacts:
Ontario Institute for Cancer Research
Contact: Christopher Needles
Manager, Editorial Services and Media Relations

Telephone: 416-673-8505
Mobile: 416-319-5252
Twitter @OICR_news

MaRS Innovation
Elizabeth Monier-Williams
Marketing and Communications Manager

Telephone: 647-260-7850
Mobile: 647-537-9097
Twitter @MaRSInnovation

Copyright © CNW Group Ltd.

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark:
Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related News Press

News and information

Oxford Instruments Asylum Research Introduces the MFP-3D InfinityTM AFM Featuring Powerful New Capabilities and Stunning High Performance April 18th, 2014

High-temperature plasmonics eyed for solar, computer innovation April 17th, 2014

INSCX™ exchange to present Exchange trade reporting mechanism for engineered nanomaterials (NMs) to UK regulation agencies, insurers and upstream/downstream users April 17th, 2014

Transparent Conductive Films and Sensors Are Hot Segments in Printed Electronics: Start-ups in these fields show above-average momentum, while companies working on emissive displays such as OLED are fading, Lux Research says April 17th, 2014

Govt.-Legislation/Regulation/Funding/Policy

Novel stapled peptide nanoparticle combination prevents RSV infection, study finds April 17th, 2014

INSCX™ exchange to present Exchange trade reporting mechanism for engineered nanomaterials (NMs) to UK regulation agencies, insurers and upstream/downstream users April 17th, 2014

UT Arlington physicist creates new nanoparticle for cancer therapy April 16th, 2014

Relieving electric vehicle range anxiety with improved batteries: Lithium-sulfur batteries last longer with nanomaterial-packed cathode April 16th, 2014

Nanomedicine

Novel stapled peptide nanoparticle combination prevents RSV infection, study finds April 17th, 2014

More effective kidney stone treatment, from the macroscopic to the nanoscale April 17th, 2014

High-temperature plasmonics eyed for solar, computer innovation April 17th, 2014

Harris & Harris Group Continues Its Blog Series to Highlight Most Impactful Portfolio Companies With Champions Oncology, Inc. April 17th, 2014

Announcements

Oxford Instruments Asylum Research Introduces the MFP-3D InfinityTM AFM Featuring Powerful New Capabilities and Stunning High Performance April 18th, 2014

High-temperature plasmonics eyed for solar, computer innovation April 17th, 2014

INSCX™ exchange to present Exchange trade reporting mechanism for engineered nanomaterials (NMs) to UK regulation agencies, insurers and upstream/downstream users April 17th, 2014

Transparent Conductive Films and Sensors Are Hot Segments in Printed Electronics: Start-ups in these fields show above-average momentum, while companies working on emissive displays such as OLED are fading, Lux Research says April 17th, 2014

Grants/Awards/Scholarships/Gifts/Contests/Honors/Records

Energy Research Facility Construction Project at Brookhaven Lab Wins U.S. Energy Secretary's Achievement Award April 16th, 2014

IDTechEx Printed Electronics Europe 2014 Award Winners April 1st, 2014

Dais Analytic Wins SBIR Grant: Dais Analytic Receives US Army Small Business Innovation Research Grant to Further Its Demonstrated Successes in Cleaning Most Forms of Wastewater March 28th, 2014

Scientists develop world’s first light-activated antimicrobial surface that also works in the dark March 24th, 2014

NanoNews-Digest
The latest news from around the world, FREE







  Premium Products
NanoNews-Custom
Only the news you want to read!
 Learn More
NanoTech-Transfer
University Technology Transfer & Patents
 Learn More
NanoStrategies
Full-service, expert consulting
 Learn More














ASP
Nanotechnology Now Featured Books




NNN

The Hunger Project







© Copyright 1999-2014 7th Wave, Inc. All Rights Reserved PRIVACY POLICY :: CONTACT US :: STATS :: SITE MAP :: ADVERTISE